JP2021523946A5 - - Google Patents

Info

Publication number
JP2021523946A5
JP2021523946A5 JP2021514457A JP2021514457A JP2021523946A5 JP 2021523946 A5 JP2021523946 A5 JP 2021523946A5 JP 2021514457 A JP2021514457 A JP 2021514457A JP 2021514457 A JP2021514457 A JP 2021514457A JP 2021523946 A5 JP2021523946 A5 JP 2021523946A5
Authority
JP
Japan
Prior art keywords
lck
amino acid
composition according
composition
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523946A (ja
JP7386852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050463 external-priority patent/WO2019218016A1/en
Publication of JP2021523946A publication Critical patent/JP2021523946A/ja
Publication of JP2021523946A5 publication Critical patent/JP2021523946A5/ja
Application granted granted Critical
Publication of JP7386852B2 publication Critical patent/JP7386852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514457A 2018-05-15 2019-05-15 ペプチド活性化剤 Active JP7386852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901673 2018-05-15
AU2018901673A AU2018901673A0 (en) 2018-05-15 Peptide Activating Agent
PCT/AU2019/050463 WO2019218016A1 (en) 2018-05-15 2019-05-15 Peptide activating agent

Publications (3)

Publication Number Publication Date
JP2021523946A JP2021523946A (ja) 2021-09-09
JP2021523946A5 true JP2021523946A5 (enExample) 2022-05-24
JP7386852B2 JP7386852B2 (ja) 2023-11-27

Family

ID=68539135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514457A Active JP7386852B2 (ja) 2018-05-15 2019-05-15 ペプチド活性化剤

Country Status (8)

Country Link
US (2) US11912789B2 (enExample)
EP (1) EP3794014A4 (enExample)
JP (1) JP7386852B2 (enExample)
KR (1) KR102918269B1 (enExample)
CN (1) CN112399970B (enExample)
AU (1) AU2019268412B2 (enExample)
CA (1) CA3100074A1 (enExample)
WO (1) WO2019218016A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518187B (zh) * 2020-04-16 2022-05-10 中国农业科学院饲料研究所 抗菌肽dn6nh2及其应用
KR20240044517A (ko) * 2021-08-20 2024-04-04 인터크 펩타이드 테라퓨틱스 리미티드 암 및 암 요법과 연관된 자가면역을 포함한 자가면역을 치료하기 위한 조성물 및 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
AU2005204275B2 (en) * 1999-06-28 2008-10-16 Inter-K Pty Limited A method of modulating integrin mediated cellular activity and agents useful for same
AU2007231835A1 (en) * 2000-12-22 2007-11-29 Inter-K Pty Limited Screening assay for an inhibitor of MAP kinase?integrin binding
CA2539914A1 (en) * 2003-09-22 2005-04-07 Acidophil Llc Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションPurdue Research Foundation キナーゼ阻害薬およびその使用
CA2697896C (en) 2007-09-18 2016-06-28 Green Peptide Co., Ltd. Ctl inducer composition
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
JP2012518602A (ja) * 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
NZ713461A (en) * 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2720705A4 (en) * 2011-06-16 2015-02-18 Jolla Inst Allergy Immunolog COMPOSITIONS, APPLICATIONS AND METHODS OF TREATING PKC-THETA PATHOLOGIES, UNWANTED IMMUNE REACTIONS AND DISEASES
WO2013110120A1 (en) 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
JP7644000B2 (ja) * 2018-05-15 2025-03-11 インテルク ペプチド セラピューティクス リミテッド 活性化剤

Similar Documents

Publication Publication Date Title
JP7360419B2 (ja) 安定化抗微生物性ペプチド
JP2021523945A5 (enExample)
Mercer et al. Peptides as the next generation of anti-infectives
JP2014521684A5 (enExample)
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
WO2007097251A1 (ja) 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
JP2008514586A5 (enExample)
CA2112907C (en) Peptide which abrogates tnf and/or lps toxicity
JP2005526833A5 (enExample)
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2021523946A5 (enExample)
US20250215054A1 (en) Compositions and methods for treatment of fungal infections
JP2009534451A5 (enExample)
JPWO2022202816A5 (enExample)
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
EP2990415B1 (en) Cyclic beta defensins analogs for the treatment of infections
CN111247162B (zh) 多黏菌素类似物及其制备方法
JP2015514771A5 (enExample)
JPWO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
US12012440B2 (en) Compositions and methods for treatment of fungal infections
JP2009515933A (ja) インフルエンザにおけるインターフェロン
WO1997048725A1 (en) Novel peptides for prevention and treatment of infection
JP2014198711A (ja) Ct阻害4価ペプチドおよびコレラ治療薬
TW476650B (en) Use of a cytokine regulatory agent to treat rheumatoid arthritis